NextCure, Inc.
NXTC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.06 | -1.07 |
| FCF Yield | -39.97% | -173.27% | -96.66% | -32.12% |
| EV / EBITDA | -1.58 | -0.48 | 0.32 | 0.02 |
| Quality | ||||
| ROIC | -31.26% | -73.95% | -18.93% | -17.28% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.85 | 1.18 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 72.40% | -74.80% | -87.37% | 40.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.36 | 0.01 | 1.54 | 1.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |